

## DRUG ALERT

### CLASS 4 MEDICINES DEFECT INFORMATION

#### Caution in Use

#### Distribute to Pharmacy / Wholesaler Level

Dear Healthcare Professional

#### Brancaster Pharma Limited

**Benzylpenicillin benzathine 1.2 Million I.U. powder and solvent for suspension for injection**

**PL 41542/0006**

Batch Number	Expiry Date	Pack Size	First Distributed
72C00215	April 2021	1	February 2020
72C00116	August 2022	1	December 2020

The batch below has been packed and is awaiting distribution:

Batch Number	Expiry Date	Pack Size	First Distributed
72N00206	May 2024	1	-

**Benzylpenicillin benzathine 2.4 Million I.U. powder and solvent for suspension for injection**

**PL 41542/0007**

Batch Number	Expiry Date	Pack Size	First Distributed
72C00216	April 2021	1	February 2020
72C00220	August 2022	1	August 2020
72C00223	February 2023	1	September 2021

The batch below has been packed and is awaiting distribution:

Batch Number	Expiry Date	Pack Size	First Distributed
72N00207	May 2024	1	-

**Active Pharmaceutical Ingredients:** Benzylpenicillin benzathine; Water for Injections



**Brief description of the problem**

Brancaster Pharma Limited have notified us of an issue relating to the label affixed to the 5mL ampoule of Water for Injections (solvent) that is packaged in each finished product pack.

This label is not in accordance with the approved marketing authorisation: it is written in French language rather than English, and relates to the approved French benzathine benzylpenicillin combination product (“Extencilline”).

The Water for Injections for the French product is identical to the approved UK product, except for the labelling on the ampoule. The label affixed to the vials of benzylpenicillin benzathine powder, outer carton of the finished product packs and patient information leaflets for the above batches are in accordance with the marketing authorisations.

**Advice for healthcare professionals**

Healthcare professionals are advised to note this issue. The Water for Injections ampoule contains 5mL water for injections; there is no risk to the quality of the reconstituted injection as a result of this issue, therefore the affected batches are not being recalled.

**Further Information**

For medical information and stock control queries please contact: [safety@brancasterpharma.com](mailto:safety@brancasterpharma.com)

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

**TO ALL CHEMISTS, DOCTORS ON THE LISTS**

Pharmaceutical Services  
2 Franklin Street  
BELFAST  
BT2 8DQ

Telephone No. 028 9536 0333

22<sup>nd</sup> March 2022

Pharmaceutical website: <http://www.hscbusiness.hscni.net>